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Summary. Background: Combined vitamin K-dependent
clotting factor (VKCF) deﬁciency type 2 (VKCFD2) is a
rare bleeding disorder caused by mutated vitamin K 2,3-
epoxide reductase complex subunit 1 (VKORC1) gene.
Methods and results: An Italian patient with moderate to
severe bleeding tendency was genotyped, and found to be
homozygous for the unique VKORC1 mutation (Arg98Trp)
so far detected in VKCFD2. The activity levels of VKCFs
were diﬀerentially reduced, and inversely related to the
previously estimated aﬃnity of procoagulant factor pro-
peptides for the c-carboxylase. The normal (factor IX) or
reduced antigen levels (other VKCFs) produced a gradient in
speciﬁc activities. Vitamin K supplementations resulted in
reproducible, fast and sustained normalization of PT and
APTT. At 24 h the activity/antigen ratios of VKCFs were
close to normal, and activity levels were completely (factor
VII and IX), virtually (prothrombin, factor X and protein C)
or partially (protein S) restored. Thrombin generation assays
showed a markedly shortened lag time. The time to peak
observed at low tissue factor concentration, potentially
mimicking the physiological trigger and able to highlight the
eﬀect of reduced protein S levels, was shorter than that in
pooled normal plasma. At 72 h the thrombin generation times
were normal, and the decrease in activity of procoagulant
VKCFs was inversely related to their half-life in plasma.
The improved coagulation phenotype permitted the unevent-
ful clinical course after invasive diagnostic procedures.
Conclusions: Modiﬁcation of coagulation phenotypes in
VKCFD2 after vitamin K supplementation was clinically
beneﬁcial, and provided valuable patterns of factor speciﬁc
biosynthesis, half-life and decay.
Keywords: VKCFD2, VKORC1 mutation, coagulation factor
levels, thrombin generation, vitamin K supplementation.
Introduction
Impaired c-carboxylation [1,2] produces multiple deﬁciency of
vitamin K-dependent coagulation factors (VKCFD), a rare
bleeding disorder inherited as an autosomal recessive trait [3].
The VKCFD type 2 (VKCFD2) is caused by defective
regeneration of vitamin K hydroquinone by the vitamin K
2,3-epoxide reductase complex subunit 1 (VKORC1) [4]. Only
one causative missense change (VKORC1 Arg98Trp) has been
found in the homozygous condition in families of Lebanese and
German origin [5,6].
In VKCFD2, the activity of the c-glutamyl carboxylase
enzyme, impaired by the limiting concentration of the vitamin
K hydroquinone, can be transiently restored by vitamin K
supplementation. These features make this condition an ideal
model to investigate in vivo the temporal variations in levels of
vitamin K-dependent factors, driven by changes in c-glutamyl
carboxylation activity. Comparison of this natural condition
with the pharmacological inhibition of the vitamin K cycle
could provide valuable information to interpret observations
obtained in plasma of patients on anticoagulant therapy [7–11].
The study of plasma phenotype variation in VKCFD2
would also contribute to validate, through in vivo observa-
tions, the cellular and molecular investigations [4,12–16]
aimed at dissecting the mechanisms through which compo-
nents of the vitamin K cycle [17] participate in the regulation
of circulating factor level activity. Moreover, an extended
analysis of levels after vitamin K supplementation in
VKCFD2 would also provide information about the natural
decay of vitamin K dependent clotting factors, of great
interest for replacement therapy in inherited coagulation
disorders [18].
As a thorough characterization of this deﬁciency by single
factor parameters and by assays integrating the contribution of
procoagulant and anticoagulant components has not been
reported, we have investigated an VKCFD2 Italian patient
over time after vitamin K supplementation.
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Patients, materials and methods
Patient and family
The proposita, a 34-year-old woman, had experienced since
childhood repeated nose and gum bleeds, menorrhagia, a
severe post-partum hemorrhage at the age of 23 requiring
blood transfusions, hemoperitoneum following ovarian cyst
rupture, and rectal bleeding. In addition she presented with
osteoporosis.
Laboratory testing of the patients plasma revealed reduced
activity levels of several procoagulant factors. Family members
showed coagulation parameters in the normal range. Informed
consent was obtained from the family members entering this
study.
DNA analysis
The screening of the molecular defect responsible for the
altered coagulation proﬁle in the proposita was performed in
both the c-glutamyl-carboxylase (GGCX) and VKORC1
genes.
Direct scanning of exons and intron-exon boundaries of
GGCX and VKORC1 genes were performed by PCR ampli-
ﬁcation followed by automated sequencing with the ABI Prism
377DNASequencer (PEApplied Biosystems, Foster City, CA,
USA). Speciﬁc primers for GGCX and VKORCI genes were
derived from the Gene Bank database (references U65896 and
AY587020, respectively). In the GGCX gene three single
nucleotide changes, the g.1156G>C (intron 1), the
g.9167T>C (exon 9), that predicts the Arg406Arg synony-
mous change, and the g.11665G>C (intron 14) were detected.
Coagulation laboratory assay
Plasma samples were withdrawn before (0 h) and after (at 4,
24, 28 and 72 h) intravenous administration of 10 mg vitamin
K (Konakion–Roche, Basel, Switzerland). Plasma samples
before and after 24 hwere also collected during a second course
of vitamin K application conducted 5 months later, before an
esophagogastroduodenoscopy and colonoscopy with biopsy.
Venous blood was drawn in sodium citrate (12.9 mmol L)1)
and immediately centrifuged at 2000 g for 20 min at 4 C.
Plasma was separated, snap-frozen, and stored in aliquots at
)80 C.
Factor clotting activities were assessed by conventional PT
(factor (F) II, FVII, FX and PS) or APTT -based assays (FIX
and PC) with the corresponding commercial factor-depleted
plasma (HemosILTM; Instrumentation Laboratory, Milan,
Italy). PT was also assayed in a FII, FVII, FIX and FX-
depleted bovine plasma triggered with bovine thromboplastin
(Pro-IL-Complex kit, HemosILTM). PC amidolytic activity
was measured chromogenically (HemosILTM Protein C).
The total activity of the protein C pathway was evaluated by
the APTT-based method Pro-C Global (Dade Behring
Diagnostics, Marburg, Germany). The normalized ratio
(PCAT-NR) of the APTT determined in the presence and in
the absence of activator Protac (PCAT:PCAT/0 ratio) was
reported.
Antigen assays
Antigen levels were measured by ELISA using a mouse
monoclonal anti-human FVII antibody, a sheep polyclonal
anti human-FVIII antibody, a goat polyclonal anti-human
FIX antibody (Afﬁnity Biologicals Inc, Ancaster, Canada), a
rabbit polyclonal anti-human FX antibody (DakoCytomation,
Glostrup, Denmark) and amousemonoclonal anti-human free
PS antibody (Instrumentation Laboratory) directed to the
C4bBP domain. Prothrombin levels were evaluated byWestern
blot analysis as previously reported for FX [19]. Upon
electrophoresis of diluted patients plasma (1:70) on a Novex
Tris-Glycine 4–20% PAA Gel (Invitrogen, Carlsbad, CA,
USA), and electroblotting onto nitrocellulose membranes
(Schleicher & Schuell Microscience, Keene, NH, USA),
prothrombin was probed by a sheep polyclonal anti-human
prothrombin-HRP (Afﬁnity, Carlsbad, CA, USA). Densito-
metric analysis of bands was conducted by the GS-700
instrument (BIORAD, Hercules, CA, USA).
FXa generation
Plasma FVII activity towards FX was assayed essentially as
previously described [20]. Generation of activated FX (FXa)
was monitored continuously by exploiting a speciﬁc ﬂuoro-
genic substrate (MeSO2-D-CHA-Gly-Arg-AMCAcOH,
American Diagnostica, Greenwich, CT, USA). Fluorescence
(360 nm excitation, 465 emission) was measured on Spectra-
FluorPlus microplate reader (TECAN, Salzburg, Austria).
Thrombin generation
Platelet-poor plasma (PPP) samples were centrifuged at
23 000 g at 4 C for 1 h before testing. Calibrated automated
thrombin activity measurement was conducted according to
Hemker et al. [21] in an automated microtiter plate ﬂuo-
rometer (Fluoroskan Ascent; Thermo Labsystems, Helsinki,
Finland) using the Thrombinoscope software (Synapse BV,
Maastricht, The Netherlands). The assays were carried out at
37 C essentially as previously reported [22]. Coagulation was
triggered in recalciﬁed PPP under the following experimental
conditions: 4 lM phospholipids (PLP, 20% phosphatidyl
serine-80% phosphatidyl choline); 1 pM recombinant human
tissue factor (TF)/4 lM PLP; 5 pM TF/4 lM PLP; 10 pM TF/
8 lM PLP. The snake venom Protac (HemosILTM; Instru-
mentation Laboratory) was used in the presence of 3.5 pM
TF/10 lM PLP. Thrombin generation was evaluated over-
time by exploiting a speciﬁc ﬂuorogenic substrate (Z-Gly-
Gly-Arg-AMC) and was conducted in parallel in each
plasma sample supplemented with a thrombin calibrator
(Synapse BV). Experiments were carried out in duplicate or
triplicate.
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Results
DNA studies
Sequencing of the VKORC1 gene showed that the proposita
was homozygous for the c.292C>T transition resulting in the
amino acid change Arg98Trp. The propositas mother, two
brothers and one sister were found to be carriers, as indicated
by the AciI restriction analysis.
Frequent polymorphisms predicting variation in coagula-
tion factor levels were also investigated. The proposita was
found to be homozygous for the )323 ins10 in F7 gene [23],
a condition associated with a remarkable reduction in FVII
levels [24].
Coagulation studies
To get a comprehensive evaluation of the hemostatic proﬁle
and of its variations following vitamin K supplementation,
APTT and PT were measured in the patients plasma before
and after intravenous supplementation of 10 mg vitamin K
(Table 1). Before treatment the APTT was mildly prolonged
and the PT-INR was remarkably increased. At 4 h a normal
APTT and a remarkable decrease of the PT-INR were
observed. The APTT was shorter than that of PNP (30 s)
both at 24 and 28 h, and at the same time points PT was
normalized. At 72 h the beneﬁcial effects of vitamin K
supplementation were noticeable, particularly for APTT.
Variations in PT and APTT were evaluated in the light of
level variations of the speciﬁc vitamin K-dependent factors.
Procoagulant factors The baseline activity levels, measured
on different occasions (Table 1), were constant for FX and
showed modest (FVII and FIX) or pronounced (prothrombin)
variations.
As the differentially reduced activity values might reﬂect the
residual carboxylase activity, we investigated their relationship
with the binding afﬁnities of carboxylase for the propeptide of
the vitamin K-dependent procoagulant factors, previously
estimated through peptide inhibition constants [25]. In two
plasma samples obtained 5 months apart before vitamin K
supplementation, mean activity levels showed a logarithmic
relation (R2 = 0.70) with the inhibition constants (Fig. 1). The
best relation was found for FVII, FX and prothrombin levels
(R2 = 0.99), which indicated that their activity was inversely
related with the afﬁnity of the vitamin K-dependent
carboxylase for coagulation factor propeptides.
For all factors an appreciable and reproducible (Table 1)
increase in activity levels was measured after vitamin K
supplementation. Plasma activity levels reached normal values
for FVII and FIX, and borderline values for FX and
prothrombin.
Levels higher than those at baseline were still detectable at
72 h, with the exception of FVII, which decreased at pretreat-
ment levels (Table 1). The decrease in levels from the peak to
72 h was inversely related to (Fig. 2) the known half-life values
of coagulation factors [26]. Particularly, the decrease showed
Table 1 Coagulation times and activity levels of vitamin K-dependent
coagulation factors measured before (0 h) and after vitamin K treatment
Plasma sampling
0 h 4 h 24 h 28 h 72 h
APTT 33 39* 26 23 24* 23 26
PT-INR 3.18 3.46* 1.66 1.15 1.14* 1.11 1.79
PT 107 37
PCAT-NR 0.64 1.29
FVII 14 10* 30 113 115* 117 19
FIX 26 21* 58 142 93* 108 67
FX 8 8* 30 68 79* 66 39
31 77 64
FII 26 13* 42 67 84* 67 43
PC 36 34* 55 92 105* 89 48
PS 27 21* 36 54 46* 50 45
*Values obtained before and after the second course of vitamin K
administration. The APTT and PT are expressed in seconds (normal
range 25–35 s and 18–27 s, respectively). The PT was measured in a
FII, FVII, FIX and FX-depleted bovine plasma triggered with bovine
thromboplastin. PCAT-NR, normalized ratio of the APTT determined
in the presence and in the absence of the protein C activator Protac.
Clotting activity (FVII, FIX, FX, FII) and amydolitic activity (PC)
levels are reported as percentage of PNP (70–120, normal range). Free
protein S antigen is reported as percentage of PNP (53–109, normal
range). FXa levels (% of PNP) measured at the peak of the FXa
generation curves.
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Fig. 1. Baseline activity level of procoagulant factors and inhibition
constants (Ki) of coagulation factor propeptides for c-carboxylase [25].
The mean activity levels measured in two independent plasma samples are
reported. Logarithmic relation between variables (R2 = 0.70).
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Fig. 2. Decrease in activity levels (expressed as percentage) from peak to
72 h and half-life of procoagulant factors. The lowest values in the half-life
range [26] were used (R2 = 0.97, exponential curve).
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the best ﬁtting (exponential curve, R2 = 0.97) with the lowest
values of the half-life range. The R2 using the highest half-life
values was 0.75.
Defective VKOR activity appeared to affect activity and
secretion of vitamin K-dependent factors to a different extent,
and was responsible for the presence of dysfunctional mole-
cules in plasma, as indicated by an excess of antigen levels (Fig.
3). FIX antigen levels were normal at baseline whereas those of
FVII and FX were similarly reduced. At 24 h antigen levels
were restored (FVII) or remarkably increased (FX).
The activity/antigen ratios at baseline and their variations
induced by vitamin K supplementation after 24 h are summa-
rized in Fig. 3. Before vitamin K administration, the unbal-
ance between activity and antigen levels was remarkable with
ratios of 0.2 (FX), 0.3 (FIX) and 0.5 (FVII and FII), which
would strongly indicate the presence of partially carboxylated
forms of vitamin K dependent clotting factors (PIVKA).
The overall dysfunctional effect of poorly carboxylated
forms was indicated by PT assays conducted in a FII, FVII,
FIX and FX-depleted bovine plasma triggered with bovine
thromboplastin (Table 1). The PT observed in the patient
(107 s, 5% of PNP) was more prolonged than those measured
in plasma from patients on anticoagulant therapy (range 44–
89 s, 7–28% of PNP).
Vitamin K administration substantially increased activity/
antigen ratios of all procoagulant factors. The increase in
amount of functional molecules was also indicated by the
amelioration of parameters of PT and APTT assays (Table 1).
However, the PT obtained in the bovine plasma (clotting time
37 s and 42% activity) was still far from normal (18–27 s).
As expected, the antigen level of FVIII (1.31 IU mL)1), not
requiring vitamin K for biosynthesis, did not change after
vitamin K administration (1.33 IU mL)1).
Anticoagulant factors Repeated measurements indicated
that the constant but defective amydolitic activity of PC at
baseline was substantially improved by vitamin K
supplementation (Table 1). Anticoagulant assays indicated a
very ample variation in PC activity (from 2% to 73% of PNP).
Assuming that amidolytic activity parallels or is lower than
antigen levels, the increase in PC speciﬁc activity (ratio from
0.06 to 0.8; Fig. 3) appears the most pronounced among the
evaluated serine proteases.
Protein S free antigen levels at baseline (Table 1) were similar
to those found in type I PS deﬁciency. Although levels were
doubled at 24 h, they were only partially restored. This pattern
was conﬁrmed in the second course of vitamin K supplemen-
tation (Table 1).
At 24 h the PS anticoagulant function, evaluated in a PT-
based assay, resulted in 58% of PNP, which roughly normal-
izes the activity/antigen ratio, as observed for vitamin K-
dependent serine proteases.
The protein C pathway was further investigated through
activation of endogenous protein C by the venom Protac in the
APTT-based assay ProC global [27] (Table 1). The normalized
ratio at baseline (NR = 0.64) was comparable with that of a
heterozygous FV Leiden plasma (NR = 0.72), and was
substantially increased by vitamin K supplementation
(NR = 1.29).
Thrombin and FXa generation assays
The vitamin K-induced modiﬁcation of thrombin generation
parameters was evaluated under different conditions (Fig. 4).
At all TF concentrations the lag-time and time to peak were
both prolonged before treatment. In two plasma samples,
obtained several months apart and assayed at 1 pMTF, the lag-
time ranged from 7.7 ± 0.01 to 9.8 ± 0.16 min and the time
to peak from 10.3 ± 0.01 to 12.8 ± 0.16 min. By comparison,
the PNP lag-time (4.5 ± 0.5 and 4.6 ± 0.16 min) and time to
peak (8.2 ± 1.17 and 8.6 ± 0.16 min) were constant. In the
absence of TF thrombin generationwas undetectable at 40 min
(not shown).
At 24 h after vitamin K supplementation, the lag-time was
similar to normal (Fig. 4). Whenmeasured at 1 pM TF (Fig. 4)
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Fig. 3. Activity/antigen ratios measured before (white column) and after
vitaminK treatment (black column). For PC the anticoagulant/amydolitic
activity ratio is reported. The antigen levels are indicated. Prothrombin
antigen levels were evaluated by densitometric analysis of Western blot.
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Fig. 4. Thrombin generation triggered with the indicated TF concentra-
tions in patient plasma, before (d) and 24 h after (s) vitamin K admin-
istration, and in PNP (–).
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the time to peak was reproducibly shorter (5.7 ± 0.33 and
6.6 ± 0.16 min) than in PNP.
Before treatment ETP values were clearly reduced at all TF
concentrations (Fig. 4), ranging from 26% (1 pM TF) to 48%
of PNP (10 pM TF). After treatment, the ETP was close to
normal, ranging from 70% (1 pM TF) to 78% (10 pM TF) of
PNP.
Normal time parameters (lag-time 4.7 ± 0.01 min, time to
peak 7.0 ± 0.01 min) and sustained ETP (61% of PNP) were
still present in the patients plasma at 72 h.
In order to enhance the contribution of the APC pathway,
thrombin generation was also evaluated in the presence of the
venom Protac (not shown). This protein C activator substan-
tially inhibited thrombin generation in PNP (61% reduction in
ETP), but was poorly effective in the patients plasma, both
before (21% reduction) and after (25% reduction) vitamin K
administration. The ETPmeasured in plasma from a protein S-
deﬁcient subject (PS:C and PS:Ag, 40%) was poorly modiﬁed
(11% decrease) after the addition of Protac.
FXa generation was measured with a speciﬁc FXa ﬂuoro-
genic substrate. The FXa generation after extrinsic activation
(Table 1) substantially increased following vitamin K admin-
istration (from 31% to 77% of PNP), and was maintained at
72 h (64% of PNP). The time to maximal FXa generation was
consistently shortened at 24 h (from 3.3 to 1.0 min) and similar
to that of PNP (1.1 min). The FXa generation levels at baseline
were comparable with FX antigen levels, and higher than FX
activity in the coagulation assay, further conﬁrming the
presence of dysfunctional FX molecules (Fig. 3).
Discussion
The genotyping and characterization of the coagulation
phenotype in the VKCFD2 patient provided us with informa-
tion that signiﬁcantly extends the knowledge of this rare
condition, and has general implications for vitamin K-depen-
dent regulation of plasma factor levels.
It is intriguing that among the several CpG sites (n = 30),
potential hot spots for missense changes in VKORC1, only
that contained in codon 98 and responsible for very low
VKORC1 activity has been found to be mutated in VKCFD2
patients from different countries [5]. Differently, several
VKORC1 mutations have been associated with warfarin
resistance [5,28,29], a major clinical phenotype in the antico-
agulant therapy.However, themutational pattern of VKCFD2
is based on very few cases, which prevents an informative
comparison.
The homozygous VKORC1 Arg98Trp change has been
found associated with heterogeneous clinical pictures, ranging
from fatal intracerebral hemorrhage after birth [6] tomoderate/
severe bleeding in adult life in the proposita. Noticeably, this
Italian patient is also homozygous for FVII polymorphisms
predicting further reduction in FVII levels, which could
exacerbate bleeding tendency. From these observations we
infer that VKCFD2, caused by a single VKORC1 mutation,
interacts with other genetic/environmental factors with a major
role in the clinical phenotype. The variations of coagulation
parameters observed in the proposita before vitamin K
supplementations further support the role of environmental
components.
The homozygous condition for the VKORC1 Arg98Trp
substitution provided us with a valuable model to investigate in
vivo the effect of the limited availability of vitamin K
hydroquinone on coagulation factor levels, and to compare
biosynthetic efﬁciency of hepatocytes subjected to genetically
induced depletion of vitamin K hydroquinone with those
poisoned by coumarin derivatives. FIX, as strongly indicated
by its normal antigen levels, showed the lowest sensitivity to the
defective vitamin K cycle, either induced by the genetic
deﬁciency of VKORC1 or warfarin therapy [8,11].
Interestingly, we found that the functional levels of proco-
agulant factors before vitamin K supplementation, which
integrate several biosynthetic and secretion steps in vivo,
inversely correlated with the afﬁnity of the vitamin K-
dependent carboxylase for coagulation factor propeptides.
Our observation supports the hypothesis that binding afﬁnities,
found in vitro to vary over a considerable range [25] and to
inﬂuence the extent of c-carboxylation [30], contribute to
predict activity level differences in vivo, particularly for FVII,
FX and prothrombin levels and to a lesser extent for FIX.
The similarly reduced protein levels of FVII, FX and PC in
the presence of a wide range of activity levels, produced a
gradient in speciﬁc activity among factors (Fig. 3), with PC
displaying the lowest value. The major effect of VKORC1
deﬁciency on this inhibitor does not appear to bemediated by a
preferential impairment in biosynthesis/secretion [14]. The low
afﬁnity of PC formembranes [31], further decreased by reduced
c-carboxylation of the Gla domain, should substantially
contribute to the extremely reduced PC functional levels in
clotting assays, in the lower range of those observed in patients
on stabilized warfarin treatment [32].
Vitamin K supplementation enabled us to investigate
temporal variations in levels of the vitamin K-dependent
factors, their effects on overall function tests and clinical
coagulation phenotype. An intravenous single dose of vitamin
K resulted in a fast, efﬁcient and sustained normalization of
coagulation times, as indicatedby the integrated assaysweused.
The fast amelioration of clotting times and of coagulation
factor activity levels at 4 h after vitamin K supplementation
could reﬂect, in addition to a de novo biosynthesis, a short time
release of proteins accumulated at the intracellular level
because of impaired c-carboxylation. This complexity limits
our ability to measure in plasma the steady state conditions of
the vitamin K-dependent factors. The restoration of the
carboxylase activity by vitamin K supplementation could be
also favoured by DT-diaphorase, a NAD(P)H dehydrogenase,
that might play a role in the generation of the hydroquinone
form of vitamin K in the presence of a high concentration of
vitamin K quinone [33], as probably occurs after vitamin K
intravenous administration.
The evaluation of the thrombin generation offered several
quantitative parameters clearly demonstrating the beneﬁcial
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effects of vitamin K supplementation, particularly the mark-
edly shortened lag-time and time to peak. In the presence of
normalized or borderline activity levels of all procoagulant
factors and PC, the partial restoration of protein S levels would
contribute to the short time parameters of thrombin genera-
tion, and to the low response to Protac. Comparison of
thrombograms obtained with different TF concentrations
provided clear evidence for the gain of information obtained
at 1 pM TF concentration, potentially mimicking the physio-
logical trigger and able to highlight the effect of reduced protein
S levels [34].
The follow up of the coagulation factor levels after transient
vitamin K-induced increase permits a parallel evaluation of
their natural decay in plasma, of great interest for replacement
regimens in inherited deﬁciencies. Strikingly, the differential
decrease in functional levels of endogenous procoagulant
vitamin K-dependent factors from the peak to 72 h supports
the lowest half-life values previously estimated in plasma for
infused single factors.
The functional rescue and the uneventful clinical course after
invasive diagnostic procedures suggest that intravenous vita-
min K administrations should be considered the ﬁrst-line
treatment in this condition. However, intravenous and oral
long-term administrations should be tested in a formal study to
evaluate the effectiveness of vitamin K administration in
prophylactic terms.
Taken together our ﬁndings in VKCFD2 validate in vivo the
cellular and molecular investigations focused on regulation of
circulating factor level activity by vitamin K cycle components,
and provide evidence for the interplay between coagulation
factor speciﬁc biosynthesis and decay after vitamin K supple-
mentation.
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